Bain Capital Life Sciences Investors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,275,552	Closed	-$37.9M	–	28
2023 Q3	$37.9M	Sell	1,275,552 -1,030,006	-45%	-$21.2M	4.24%	7
2023 Q2	$41.5M	Hold	2,305,558	–	–	4.28%	6
2023 Q1	$37M	Hold	2,305,558	–	–	4.63%	7
2022 Q4	$42.2M	Hold	2,305,558	–	–	4.72%	7
2022 Q3	$45.3M	Hold	2,305,558	–	–	5.41%	7
2022 Q2	$43M	Buy	2,305,558 +275,857	+14%	+$5.51M	5.04%	7
2022 Q1	$44.6M	Hold	2,029,701	–	–	4.33%	7
2021 Q4	$57.7M	Buy	2,029,701 +350,000	+21%	+$8.63M	4.57%	7
2021 Q3	$35.4M	Hold	1,679,701	–	–	2.19%	13
2021 Q2	$31.7M	Buy	1,679,701 +608,273	+57%	+$10.7M	2.07%	11
2021 Q1	$16.4M	Hold	1,071,428	–	–	0.93%	20
2020 Q4	$15.1M	Hold	1,071,428	–	–	0.95%	17
2020 Q3	$16.8M	Hold	1,071,428	–	–	1.56%	16
2020 Q2	$18.8M	Buy	+1,071,428	New	+$18.3M	1.97%	12

Other funds holding CRNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bain Capital Life Sciences Investors's CRNX Position: Q4 2023 in Review

Bain Capital Life Sciences Investors sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 1,275,552 shares — an estimated $37.9M sold.

Bain Capital Life Sciences Investors first reported a position in CRNX in Q2 2020 and held it in 14 quarters. The position peaked at $57.7M in Q4 2021. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

Bain Capital Life Sciences Investors reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,275,552 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $37.9M.
Bain Capital Life Sciences Investors first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Bain Capital Life Sciences Investors's Crinetics Pharmaceuticals position peaked at $57.7M in Q4 2021.
181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.